Revolo Biotherapeutics

Revolo Biotherapeutics is a biotechnology startup founded in 2011, headquartered in the United States. The company's slogan, "Analyze | Reset | Revolutionize," encapsulates its mission to develop revolutionary therapies for autoimmune and allergic diseases. Its two promising drug candidates, ‘1805 and ‘1104, have shown potential in resetting the immune system to achieve long-term remission in patients.

The innovative approach of ‘1805, a modified analogue of a key immune function molecule, is currently in clinical development for moderate-to-severe rheumatoid arthritis and non-infectious uveitis. On the other hand, ‘1104, a peptide derived from a natural immune-regulatory protein, is undergoing clinical development for patients with eosinophilic esophagitis (EoE) and allergic disease.

Notably, Revolo Biotherapeutic’s assets offer a disease-agnostic mechanism of action, providing a potential platform for developing treatments for various autoimmune and allergic conditions. The startup recently secured a significant £40.60M Series B investment on 21 September 2020, with backing from prominent investors including 24Haymarket, Metellus, and Morningside Venture Investments.

With its revolutionary therapies and strong investor support, Revolo Biotherapeutics stands at the forefront of innovation in biotechnology and healthcare, positioning itself as a key player in the quest to revolutionize treatments for autoimmune and allergic diseases. Learn more about the company at www.revolobio.com.